



News 2008 – 2007 – 2006 – 2005 – 2004 - 2003

- June 23 - July 5 2008: - Treviso, Italy. Dr. Buyse, Meta Analysis, invited lecture at the 2008 Edition of the Summer School On Modern Methods in Epidemiology and Biostatistics. Courses on both introductory and more advanced epidemiology and biostatistics, given in a two week program, will be run by faculties from Harvard School of Public Health and Karolinska Institutet. In this edition few more courses are added: Meta-Analysis, Monitoring and Evaluation of Health Programs, and Evidence Based Public Health. All courses will be using Stata. Please visit the course homepage for more information about the course:
<http://www.biostat.epi.org>
- February 1, 2007: As part of a continuous effort to improve our services, IDDI is pleased to announce the following promotions: Linda Danielson to the position of Director of Biometry and Judith De Kempeneer to the position of Director of Projects and Contracts.
- October 20, 2006: IDDI celebrated its 15th Anniversary and the move to its new headquarters.
- IDDI is pleased to announce that Linda Danielson has joined the company as Senior Statistical Advisor. She has over 15 years' experience in the field and strengthens the team with her Protocol, SAP, Regulatory, and Medical Writing experience.
- IDDI and Cytel Inc. have entered into a strategic technology collaboration to provide a Web services-based software platform for integrated randomization and IVRS technology and services.
- February 2006: In the context of its on-going Process Improvement, IDDI put a new Customer Satisfaction Survey in place.
- February 2005: IDDI Reports Successful Partnership with Eyetech and Pfizer for FDA Approval of Macugen for Treatment of Age-Related Macular Degeneration. IDDI's Data Management and Statistical Services Contributed to Approval...
- May 2004: Article written by Marc Buyse and Damian McEntegart. Mr Mc Entegart, Statistics and Special Projects Manager (ClinPhone Ltd) and Mr Buyse, Executive Director (IDDI) are the authors of an article published recently in the Applied Clinical Trials magazine. The article's title is: Achieving Balance in Clinical Trials: An Unbalanced View from EU regulators.

IDDI's Scientific Workshops 2003-2004-2005

IDDI organizes on a regular basis scientific seminars in Europe and USA to present and debate new trends in specific areas of clinical research.

The first round of seminars (years 2003-2004) was dedicated to

"Trends in the design and the conduct of early cancer clinical trials"

Date	Location	Invited Speaker and Topic
30 September 2003	London	Dr. Eric Kaldjian , Pfizer Global Research & Development, Ann Arbor, USA <i>"Biomarkers and Decision-Making in Targeted Therapy Development"</i>
4 November 2003	Montreal	Prof. Brian Leyland-Jones , McGill University and Chief Executive Officer, Xanthus Life Sciences, Montreal, Canada <i>"Targeted Therapy: A New Standard of Care in Cancer"</i>
2 March 2004	Boston	Dr. Thomas J. Schuetz , Chief Medical Officer, Therion Biologics, Boston, USA <i>"Clinical Trials in Oncology: What is the Role of Surrogate Endpoints?"</i>
29 April 2004	New York	Dr. Frank Richardson , Director, Safety Assessment and Biomarkers, OSI Pharmaceuticals, Inc., Boulder, USA <i>"Molecular Biomarkers in Development at OSI"</i>
27 May 2004	Copenhagen	Prof. Olli-P Kallioniemi , Medical Biotechnology, VTT Technical Research Centre of Finland & University of Turku, Finland <i>"Biochip Technologies for Anti-Cancer Drug Discovery and Personalised Oncology"</i>

The second round of seminars (years 2004-2005) was dedicated to

"Interim analyses and Data Monitoring Committees"

Date	Location	Invited Speaker and Topic
21 October 2004	Boston	Dr. Jay Herson , Statistical Consultant, Bethesda, USA <i>"The Future Of Interim Analysis in Clinical Trials"</i>
9 November 2004	London	Dr. Kevin Carroll , Statistical Expert for Global Oncology and Worldwide Statistical Leader for Iressa at AstraZeneca Pharmaceuticals, UK <i>"The IDMC, the Steering Committee and the Sponsor (or The Good, The Bad and The Ugly) - Harmony or Acrimony? Challenges in Managing Interim Analyses in Oncology"</i>
16 March 2005	Paris	Dr. Andrew Kramar , Head of Biostatistics Unit at the Val d'Aurelle Regional Cancer Centre, Montpellier, France <i>"Early Stopping Rules in Clinical Trials based on Sequential Monitoring of Serious Adverse Events"</i>